Mark Epping-Jordan

Title: Mark Epping-Jordan: Innovator in Central Nervous System Therapeutics

Introduction

Mark Epping-Jordan, located in Nyon, Switzerland, is a notable inventor with a total of five patents to his name. His work primarily focuses on developing novel compounds aimed at modulating metabotropic glutamate receptors, which play a crucial role in the treatment of various central nervous system (CNS) disorders.

Latest Patents

Among his latest innovations are two significant patents. The first is titled "Alkynyl derivatives as modulators of metabotropic glutamate receptors." This invention relates to new compounds that are effective modulators of the mGluR5 receptor subtype, which is instrumental in addressing CNS disorders and other related conditions. The second patent, "Allosteric modulators of metabotropic glutamate receptors," also centers on new compounds that target the mGluR5 receptors, demonstrating their potential in preventing or treating similar CNS disorders.

Career Highlights

Mark Epping-Jordan is currently associated with Addex Pharma, S.A., a company dedicated to innovating therapeutics in the pharmaceutical industry. His expertise in neuropharmacology and medicinal chemistry has significantly contributed to the firm’s research agenda and product pipeline.

Collaborations

Throughout his career, Mark has worked alongside several talented professionals, including Anne-Sophie Bessis and Jean-Philippe Rocher. This collaborative spirit fosters an environment of innovation, allowing for the exploration of groundbreaking therapeutic solutions.

Conclusion

With a robust portfolio of patents and a steadfast commitment to advancing CNS therapeutic options, Mark Epping-Jordan stands out as an influential figure in the field of pharmaceutical research. His contributions are not only paving the way for future innovations but are also essential in addressing critical health issues related to central nervous system disorders.